

What is claimed is:

- Sub a1
1. An adjuvant composition comprising a first adjuvant, where said first adjuvant comprises amorphous calcium phosphate.
 2. A composition of claim 1, further comprising particles of said first adjuvant.
 3. A composition of claim 2, wherein said particles have a diameter between 0.1 nm and 900 nm.
 4. A composition of claim 3, wherein 1-100% by weight of said composition consists of said particles having a diameter between 0.1 nm and 900 nm.
 5. A composition of claim 4, wherein 25-100% by weight of said composition consists of said particles having a diameter between 0.1 nm and 900 nm.
 6. A composition of claim 1, wherein said first adjuvant is strongly resorbable.
 7. A composition of claim 1, formulated as an injectable paste.
 8. A composition of claim 1 further comprising a second adjuvant.
- Sub B2

Sub
C2

9. A composition of claim 8, wherein said second adjuvant is selected from: muramyl dipeptide, aluminum hydroxide, aluminum phosphate, hydroxyapatite, Incomplete Freund's Adjuvant, Complete Freund's Adjuvant and polymers.

10. A composition of claim 1 further comprising an antigen.

11. A composition of claim 1 further comprising a cytokine.

12. A composition of claim 11, wherein said cytokine is selected from: IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-11, IL-13, G-CSF, IL-15, GM-CSF, OSM, LIF, IFN- γ , IFN- α , IFN- β , B7.1, B7.2, TNF- α , TNF- β , LT- β , CD40 ligand, Fas ligand, CD27 ligand, CD30 ligand, 4-1BBL, IL-8, MCP-1, MIP- α , MIP- β , RANTES, TGF- β , IL-1 α , IL-1 β , IL-1 RA, IL-10, IL-12, and MIF.

13. A method for stimulating an immune response in a mammal, said method comprising administering to the mammal a composition comprising amorphous calcium phosphate.

14. A method for increasing immunogenicity of an antigen in a mammal, said method comprising co-administering both the antigen a composition comprising amorphous calcium phosphate.

Sub
a2

00153133.001533

15. An adjuvant composition comprising a first adjuvant, where said first adjuvant comprises poorly crystalline apatitic calcium phosphate.

16. A composition of claim 15, further comprising particles of said first adjuvant.

17. A composition of claim 16, wherein said particles have a diameter between 0.1 nm and 900 nm.

18. A composition of claim 15, wherein 25-100% by weight of said composition consists of said particles having a diameter between 0.1 nm and 900 nm.

19. A composition of claim 15, wherein said first adjuvant is strongly resorbable.

20. A composition of claim 15, formulated as an injectable paste.

21. A composition of claim 15 further comprising a second adjuvant.

22. A composition of claim 21, wherein said second adjuvant is selected from: muramyl dipeptide, aluminum hydroxide, aluminum phosphate,

09153133 "001599

Sub
C4

Sub
C4
hydroxyapatite, Incomplete Freund's Adjuvant, Complete Freund's Adjuvant
and polymers.

23. A composition of claim 15 further comprising an antigen.

24. A composition of claim 15 further comprising a cytokine.

25. A composition of claim 24, wherein said cytokine is selected from: IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-11, IL-13, G-CSF, IL-15, GM-CSF, OSM, LIF, IFN- γ , IFN- α , IFN- β , B7.1, B7.2, TNF- α , TNF- β , LT- β , CD40 ligand, Fas ligand, CD27 ligand, CD30 ligand, 4-1BBL, IL-8, MCP-1, MIP- α , MIP- β , RANTES, TGF- β , IL-1 α , IL-1 β , IL-1 RA, IL-10, IL-12, and MIF.

26. A method for stimulating an immune response in a mammal, said method comprising administering to the mammal a composition comprising poorly crystalline apatitic calcium phosphate.

27. A method for increasing immunogenicity of an antigen in a mammal, said method comprising co-administering both the antigen a composition comprising poorly crystalline apatitic calcium phosphate.

28. An adjuvant composition comprising
a first adjuvant, where said first adjuvant comprises calcium phosphate; and

an adjuvanticity enhancing means wherein said enhancing means is selected from the group consisting of exogenous enhancing means or endogenous enhancing means.

29. A composition of claim 28, further comprising particles of said first adjuvant.

30. A composition of claim 28, wherein said first adjuvant is strongly resorbable.

31. A composition of claim 28, formulated as an injectable paste.

32. A composition of claim 28, wherein said adjuvanticity enhancing means is a second adjuvant.

33. A composition of claim 32, wherein said second adjuvant is selected from: muramyl dipeptide, aluminum hydroxide, aluminum phosphate, hydroxyapatite, Incomplete Freund's Adjuvant, Complete Freund's Adjuvant and polymers.

34. A composition of claim 28 further comprising an antigen.

09153133.091533

Sub
a4

35. A composition of claim 28, wherein said adjuvanticity enhancing means is a cytokine.

36. A composition of claim 35, wherein said cytokine is selected from: IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-11, IL-13, G-CSF, IL-15, GM-CSF, OSM, LIF, IFN- γ , IFN- α , IFN- β , B7.1, B7.2, TNF- α , TNF- β , LT- β , CD40 ligand, Fas ligand, CD27 ligand, CD30 ligand, 4-1BBL, IL-8, MCP-1, MIP- α , MIP- β , RANTES, TGF- β , IL-1 α , IL-1 β , IL-1 RA, IL-10, IL-12, and MIF.

37. A method for stimulating an immune response in a mammal, ~~said method comprising administering to the mammal a composition comprising calcium phosphate and an adjuvanticity enhancing means.~~

Sub
a5

add
a6